A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Gynecologic oncology 2011 Jun 121 (3): 455-61.
Usha Lydia, Sill Michael W, Darcy Kathleen M, Benbrook Doris M, Hurteau Jean A, Michelin David P, Mannel Robert S, Hanjani Parviz, De Geest Koen, Godwin Andrew
PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2011 Jan 71 (1): 82-8.
Pu Xia, Hildebrandt Michelle A T, Lu Charles, Lin Jie, Stewart David J, Ye Yuanqing, Gu Jian, Spitz Margaret R, Wu Xife